Komori
Haba Laboratories (4925) · InitiativeAdvanced

Investment to strengthen production quality control

First written in FY2022. 1 of 4 entries say "Restated". Latest entry: FY2026.

4entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2022 – FY2023-Q1ReframedFY20232022: 220222023: 120232024: 020242025: 020252026: 12026
Same theme, other companies
Strengthening Quality Control Systems and Quality No. 1A theme 135 companies write about · 1 as a headwind · 135 as a tailwind

The whole theme swung hardest in 2026: 8 of 64 companies on the "Worse" side.

41 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 135 companies compared. The sentences above are computed from all 135.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「In the cosmetics business, based on the Second Medium-Term Management Plan, the company conducted user research, home-use tests, and safety and preservative-efficacy tests for products under development as part of its efforts to renew its core skincare products in preparation for launching new products.」

    The company strengthened safety and quality control through specific development processes comprising user research, home-use tests, safety tests and preservative-efficacy tests.
  2. FY2023ReframedAnnual report

    「In addition, with safe, environmentally conscious product development and product manufacturing under thorough hygiene controls as key priorities, we are working to develop and manufacture high-functionality, high-quality products using proprietary technologies.」

    The company reframed its previous investment policy for strengthening quality control as a product development and manufacturing policy encompassing safe, environmentally conscious product development and thorough hygiene controls.
  3. FY2023-Q1RestatedAnnual report

    「There were no significant changes during the first quarter cumulative consolidated period to the management policies, management strategies or other matters established by our group.」

    The company stated that there had been no material changes to its existing management strategy, including its investment policy for strengthening production quality control.
  4. FY2022First statedAnnual report

    「In production, we will make investments to further strengthen quality control.」

    The company identified for the first time investment aimed at strengthening quality control, rather than production capacity, as a priority issue.
Moved together

"Return to revenue and profit growth and expansion of sales centered on basic skincare products" moved the same way as this thread, in the same document, in 2 of its 4 moves.

22★12
  1. ★This thread
  2. 1Return to revenue and profit growth and expansion of sales centered on basic skincare products2×
  3. 2Group-wide talent development and personnel allocation2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Haba Laboratories's next results are scheduled for 2026-11-13. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.